Treatment with evenamide was generally well-tolerated, although two patients discontinued treatment due to seizure and atrial fibrillation, respectively. The study was designed to assess safety and preliminary efficacy.
Evenamide, an oral drug, has a different mechanism of action to other available antipsychotics. It is in development as an add-on to existing schizophrenia treatments, and the company hopes that it will have potential to address harder-to-treat negative symptoms of the disease.
looking for medication that treat negative symptoms .!!
Means .??? to be taken with other medication like dopamine blocker …!!
Yes. It’s an add on to an existing AP.
Maybe this added to iti-007 would be a good combo. If iti-007 ever makes it to market.
Then again maybe min-101 would work on its own.
But there’s a lot of promising activity at the moment.
@MeghillaGorilla1 might be interested in this too.
Yea @everhopeful. I definitely am. I’m on a low dose of latuda and I don’t know how much more I can stand.
If ITI makes it to the market, and it works keeping the psychosis away. It would be a major improvement on what we’ve got now.
Otherwise the next drug won’t be out for a few years is what I’m thinking, min 101 right?
This was previous post.
I hope it’s good, but most likely I will end up hating it… I hope not.